Market Overview

Global Computer-Aided Drug Discovery Services Market Report, 2018-2030 -


The "Computer-Aided
Drug Discovery Services Market, 2018-2030"
report has been
added to's offering.

The Computer-Aided Drug Discovery Services Market, 2018-2030' report
features an extensive study on the current landscape and the likely
future potential of the players providing CADD services for drug
discovery. The study provides an in-depth analysis, highlighting the
capabilities of a diverse set of companies that offer such services
across different stages of drug discovery, such as target
identification, target validation, hit generation, hit-to-lead and lead

Given the increase in complexity of the drug discovery process, the
overall R&D spending in the pharmaceutical/biotechnology sector has
grown from around USD 128 billion in 2008 to USD 158 billion in 2017. As
a result, the industry is currently under tremendous pressure not only
to meet the expectations of a growing patient population, but also to
identify ways to mitigate the risks associated with novel drug discovery
programs to avoid failure.

The early stages of research related to drug discovery, including the
identification of a relevant biological target and a viable lead
compound, play a crucial role in the overall success of a drug candidate
in preclinical and clinical studies. It is also worth noting that the
process of drug discovery is extremely demanding, both in terms of
capital requirements and time. Moreover, there is always a high risk of
failure associated with R&D programs and, considering the increasing
regulatory stringency, the approval of new drugs has become
significantly more difficult.

Over the years, various computational tools and services have emerged,
enabling the selection, modeling, analysis and optimization of potential
lead candidates. The predictive power of computer-aided drug discovery
(CADD) has proven to be extremely advantageous, allowing researchers to
bypass the random screening of billions of molecules across hundreds of
biological targets. As a result, players offering novel in silico drug
discovery services, such as CADD, have now become an integral part of
the pharmaceutical industry.

According to industry experts, almost 30% of the total cost and time
invested in developing a new drug can be saved by utilizing such
services. Owing to the significant cost benefits offered by such
approaches, the adoption of CADD is anticipated to increase in the
coming years. Furthermore, the growing number of drug discovery
projects, coupled to their rapid progression through various stages of
drug discovery, is expected to continue to create an increasing demand
for computational services.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Profiles: North America

6. Company Profiles: Europe

7. Company Profiles: Asia-Pacific

8. Funding And Investment Analysis

9. Company Valuation Analysis

10. Survey Analysis

11. Cost Saving Analysis

12. Market Forecast

13. CADD And Future Trends In Drug Discovery

14. Executive Insights

15. Appendix 1: Tabulated Data

16. Appendix 2: List Of Companies And Organizations

17. Appendix 3: Non-Computational Methods For Drug Discovery

For more information about this report visit

View Comments and Join the Discussion!